Targeted and global pharmacometabolomics in everolimus-based immunosuppression: association of co-medication and lysophosphatidylcholines with dose requirement
Dorothea Lesche, Vilborg Sigurdardottir, Alexander B Leichtle, Christos T Nakas, Uwe Christians, Lars Englberger, Martin Fiedler, Carlo R Largiader, Paul Mohacsi, Johanna Sistonen
Metabolomics | SPRINGER | Published : 2018
Awarded by United States National Institutes of Health
The study was funded by grants from the Foundation for Pathobiochemistry and Molecular Diagnostics of the German Society of Clinical Chemistry and Laboratory Medicine to J.S., from the United States National Institutes of Health (NICHD R01 HD070511) to U.C., and from the Katharina Huber-Steiner foundation to P.M.